Market Place
Sourcing Support
Takeda Announces Phase 3 Trial of ALUNBRIG® (brigatinib) Met Primary Endpoint
22 Jan 2021 //
TAKEDAONCOLOGY
Alunbrig scores NICE backing for ALK-positive lung cancer
11 Dec 2020 //
PHARMATIMES
NICE authorises Takeda`s Alunbrig for ALK-positive advanced NSCLC
10 Dec 2020 //
PHARMAFILE
ALUNBRIG?(brigatinib) now available on the NHS in England
10 Dec 2020 //
PHARMIWEB
Takeda Presents New Data On Scientific Advances In Lung Cancer At ESMO
21 Sep 2020 //
BUSINESSWIRE
New US approval for Takeda’s Alunbrig
25 May 2020 //
PHARMA TIMES
U.S. FDA Approves Takeda’s ALUNBRIG® (brigatinib) as a First-Line Treatment
22 May 2020 //
BUSINESSWIRE
U.S. FDA Approves Takeda’s ALUNBRIG® (brigatinib) as a First-Line Treatment
22 May 2020 //
BUSINESSWIRE
Expanded EU approval for Takeda`s Alunbrig
08 Apr 2020 //
PHARMATIMES
Takeda’s Alunbrig receives European marketing approval for ALK+ NSCLC
07 Apr 2020 //
PHARMABIZ
CHMP Recommends One New Drug, Begins Review of Indian CRO
29 Feb 2020 //
RAPS
Takeda Announces U.S. FDA Grants Priority Review for sNDA for ALUNBRIG®
24 Feb 2020 //
BUSINESSWIRE
Takeda says cancer drug Alunbrig shows longer benefit vs. crizotinib
25 Nov 2019 //
REUTERS
Takeda eyes Alunbrig earlier lung cancer use as 2-year data trounce of Xalkori
23 Nov 2019 //
FIERCE PHARMA
Takeda to Showcase Growing Pipeline & Diversified Portfolio of Oncology Products
16 May 2019 //
BUSINESSWIRE
EU approval for Takeda`s Alunbrig in ALK+ advanced non-small cell lung cancer
29 Nov 2018 //
PHARMA FILE
Takeda Pharma`s Alunbrig (brigatinib) Receives Approval in Europe
27 Nov 2018 //
EMA
U.S. FDA Approves LORBRENA® (lorlatinib) for met NSCLC
02 Nov 2018 //
BUSINESSWIRE
Pfizer racks up 3rd cancer drug OK, but can it replace regular price hikes?
02 Nov 2018 //
ENDPTS
Takeda to Present Results on Efficacy of ALUNBRIG® (brigatinib) vs Crizotinib
19 Oct 2018 //
BUSINESSWIRE
Preliminary NICE ‘no’ for Takeda’s Alunbrig
03 Oct 2018 //
PHARMA TIMES
F-Prime, Atlas lead cancer startup Akrevia to $30M A round
27 Sep 2018 //
FIERCE BIOTECH
Takeda`s Alunbrig trounces Pfizer drug in bid for earlier ALK lung cancer use
26 Sep 2018 //
FIERCE PHARMA
Takeda to Present Positive Data from ALUNBRIG® (brigatinib) ALTA-1L Trial
26 Sep 2018 //
BUSINESSWIRE
Takeda Receives Positive CHMP Opinion Recommending ALUNBRIG® (brigatinib)
22 Sep 2018 //
BUSINESSWIRE
CHMP Backs 13 New Medicines, Maintains Negative Opinion of Sarepta’s Exondys
21 Sep 2018 //
RAPS
Takeda lung cancer drug gets European panel nod
21 Sep 2018 //
ECONOMIC TIMES
Takeda Announces Phase 3 Trial of ALUNBRIG® (brigatinib) Met Primary Endpoint
31 Jul 2018 //
BUSINESSWIRE
Takeda Announces Phase III Trial of ALUNBRIG For Lung Cancer
26 Jul 2018 //
BIOSPECTRUM
ASCO Soundbites, 2018 edition: Comments candid
04 Jun 2018 //
FIERCE PHARMA
Takeda to Highlight Broad Oncology Portfolio and Pipeline Data at ASCO
19 May 2018 //
BUSINESSWIRE
Pfizer files third-gen ALK inhibitor for lung cancer
14 Feb 2018 //
PMLIVE
